Renovis is a biopharmaceutical company that seeks to improve the lives of patients suffering from neurological disease with novel drugs that renew, restore, and repair the nervous system. The Company is developing REN-1654, a Phase II drug for neuropathic pain, and REN-213, a drug for post-operative pain that will enter Phase I later in 2003. Renovis will be entitled to future milestones and royalties in connection with the successful development of Cerovive™, which is in pivotal Phase III clinical trials for acute ischemic stroke and is licensed to AstraZeneca. In addition to its clinical candidates, Renovis has preclinical programs, discovery research, and specialized chemistry currently focused in the areas of pain and neuroinflammation.
Renovis is now a wholly owned subsidiary of Evotec, AG.
|08/03/03||Series E||45M||Massachusetts Institute of Technology, YankeeTek, Alliance Capital Management, FA Technology Ventures, Warner Music, San Francisco Arts Fund, Tristate, Globespan, Lake Capital, Centiva Capital, Strategic Investors Amdocs||Unknown|